Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2006, Article ID 17898, 7 pages
http://dx.doi.org/10.1155/MI/2006/17898
Research Communication

Circulating Total and Active Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Systemic Lupus Erythomatosus

1Department of Dermatology and Venerology, Medical University of Lodz, Krzemieniecka 5, Lodz 94-017, Poland
2Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital in Lodz, Pabianicka 62, Lodz 93-513, Poland
3Department of Immunology and Infectious Biology, University of Lodz, Banacha 12/16, Lodz 90-237, Poland

Received 1 September 2005; Accepted 20 October 2005

Copyright © 2006 Ewa Robak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D S Pisetsky, G Gilkeson, and E W St Clair, “Systemic lupus erythematosus. Diagnosis and treatment,” Medical Clinics of North America, vol. 81, no. 1, pp. 113–128, 1997. View at Publisher · View at Google Scholar
  2. A J Swaak, J C Nossent, and R J Smeenk, “Systemic lupus erythematosus,” International Journal of Clinical & Laboratory Research, vol. 22, no. 4, pp. 190–195, 1992. View at Google Scholar
  3. M Walchner, M Meurer, G Plewig, and G Messer, “Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus,” International Journal of Dermatology, vol. 39, no. 5, pp. 383–388, 2000. View at Publisher · View at Google Scholar
  4. E Robak, A Wozniacka, A Sysa-Jedrzejowska, H Stepien, and T Robak, “Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity,” European Cytokine Network, vol. 12, no. 3, pp. 445–452, 2001. View at Google Scholar
  5. H M Belmont, S B Abramson, and J T Lie, “Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium,” Arthritis & Rheumatism, vol. 39, no. 1, pp. 9–22, 1996. View at Google Scholar
  6. E Robak, A Sysa-Jedrzejowska, and T Robak, “Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus,” Mediators of Inflammation, vol. 12, no. 5, pp. 293–298, 2003. View at Publisher · View at Google Scholar
  7. K L Talks and A L Harris, “Current status of antiangiogenic factors,” British Journal of Haematology, vol. 109, no. 3, pp. 477–489, 2000. View at Publisher · View at Google Scholar
  8. L J McCawley and L M Matrisian, “Matrix metalloproteinases: they're not just for matrix anymore!,” Current Opinion in Cell Biology, vol. 13, no. 5, pp. 534–540, 2001. View at Publisher · View at Google Scholar
  9. C Matache, M Stefanescu, C Dragomir et al., “Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus,” Journal of Autoimmunity, vol. 20, no. 4, pp. 323–331, 2003. View at Publisher · View at Google Scholar
  10. A H Baker, D R Edwards, and G Murphy, “Metalloproteinase inhibitors: biological actions and therapeutic opportunities,” Journal of Cell Science, vol. 115, no. pt 19, pp. 3719–3727, 2002. View at Publisher · View at Google Scholar
  11. J F Jr Woessner, “Matrix metalloproteinases and their inhibitors in connective tissue remodeling,” The FASEB Journal, vol. 5, no. 8, pp. 2145–2154, 1991. View at Google Scholar
  12. E Lambert, E Dasse, B Haye, and E Petitfrere, “TIMPs as multifacial proteins,” Critical Reviews in Oncology/Hematology, vol. 49, no. 3, pp. 187–198, 2004. View at Publisher · View at Google Scholar
  13. D E Gomez, D F Alonso, H Yoshiji, and U P Thorgeirsson, “Tissue inhibitors of metalloproteinases: structure, regulation and biological functions,” European Journal of Cell Biology, vol. 74, no. 2, pp. 111–122, 1997. View at Google Scholar
  14. L Guedez, W G Stetler-Stevenson, L Wolff et al., “In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1,” The Journal of Clinical Investigation, vol. 102, no. 11, pp. 2002–2010, 1998. View at Google Scholar
  15. G S Makowski and M L Ramsby, “Concentrations of circulating matrix metalloproteinase 9 inversely correlate with autoimmune antibodies to double stranded DNA: implications for monitoring disease activity in systemic lupus erythematosus,” Molecular Pathology : MP, vol. 56, no. 4, pp. 244–247, 2003. View at Publisher · View at Google Scholar
  16. J F Muñoz-Valle, M Vázquez-Del Mercado, T García-Iglesias et al., “T(H)1/T(H)2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients,” Clinical and Experimental Immunology, vol. 131, no. 2, pp. 377–384, 2003. View at Google Scholar
  17. C Mawrin, A Brunn, C Röcken, and J M Schröder, “Peripheral neuropathy in systemic lupus erythematosus: pathomorphological features and distribution pattern of matrix metalloproteinases,” Acta Neuropathologica, vol. 105, no. 4, pp. 365–372, 2003. View at Google Scholar
  18. S Zucker, N Mian, M Drews et al., “Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity,” The Journal of Rheumatology, vol. 26, no. 1, pp. 78–80, 1999. View at Google Scholar
  19. A Faber-Elmann, Z Sthoeger, A Tcherniack, M Dayan, and E Mozes, “Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus,” Clinical and Experimental Immunology, vol. 127, no. 2, pp. 393–398, 2002. View at Publisher · View at Google Scholar
  20. E Toubi, A Kessel, G Grushko, E Sabo, M Rozenbaum, and I Rosner, “The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity,” Clinical and Experimental Rheumatology, vol. 20, no. 2, pp. 221–224, 2002. View at Google Scholar
  21. E M Tan, A S Cohen, J F Fries et al., “The 1982 revised criteria for the classification of systemic lupus erythematosus,” Arthritis & Rheumatism, vol. 25, no. 11, pp. 1271–1277, 1982. View at Google Scholar
  22. M H Liang, S A Socher, M G Larson, and P H Schur, “Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus,” Arthritis & Rheumatism, vol. 32, no. 9, pp. 1107–1118, 1989. View at Google Scholar
  23. A Wierzbowska, H Urbańska-Ryś, and T Robak, “Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma,” British Journal of Haematology, vol. 105, no. 2, pp. 412–419, 1999. View at Publisher · View at Google Scholar
  24. E Robak, A Wozniacka, A Sysa-Jedrzejowska, H Stepien, and T Robak, “Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus,” Lupus, vol. 11, no. 6, pp. 348–355, 2002. View at Publisher · View at Google Scholar
  25. Y Liu, M Zheng, W H Yin, and B Zhang, “Relationship of serum levels of HGF and MMP-9 with disease activity of patients with systemic lupus erythematosus,” Zhejiang Da Xue Xue Bao Yi Xue Ban, vol. 33, no. 4, pp. 340–343, 348, 2004. View at Google Scholar
  26. M H Tayebjee, K T Tan, R J MacFadyen, and G Y Lip, “Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity,” Journal of Internal Medicine, vol. 257, no. 1, pp. 110–116, 2005. View at Publisher · View at Google Scholar
  27. M H Tayebjee, G Y Lip, A D Blann, and R J MacFadyen, “Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2,” Thrombosis Research, vol. 115, no. 3, pp. 205–210, 2005. View at Publisher · View at Google Scholar